Literature DB >> 11452363

The D13S171 marker, misannotated to BRCA2, links the AS3 gene to various cancers.

P Geck, C Sonnenschein, A M Soto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11452363      PMCID： PMC1235319          DOI： 10.1086/321968

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN： 0002-9297            Impact factor:   11.025


× No keyword cloud information.
  19 in total

1.  Polymorphism and allelic loss at the AS3 locus on 13q12-13 in esophageal squamous cell carcinoma.

Authors:  H Harada; N Uchida; Y Shimada; H Kumimoto; M Shinoda; M Imamura; K Ishizaki
Journal:  Int J Oncol       Date:  2001-05       Impact factor: 5.650

2.  Founder mutations of BRCA1 and BRCA2 in North American families of Polish origin that are affected with breast cancer.

Authors:  P de los Rios; E Jack; G Kuperstein; H Lynch; J Lubinski; S A Narod
Journal:  Am J Hum Genet       Date:  2001-02       Impact factor: 11.025

3.  Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.

Authors:  B Górski; T Byrski; T Huzarski; A Jakubowska; J Menkiszak; J Gronwald; A Pluzańska; M Bebenek; L Fischer-Maliszewska; E Grzybowska; S A Narod; J Lubiński
Journal:  Am J Hum Genet       Date:  2000-04-28       Impact factor: 11.025

4.  Loss of heterozygosity at chromosome 13q in hepatocellular carcinoma: identification of three independent regions.

Authors:  Y W Lin; J C Sheu; L Y Liu; C H Chen; H S Lee; G T Huang; J T Wang; P H Lee; F J Lu
Journal:  Eur J Cancer       Date:  1999-11       Impact factor: 9.162

5.  Androgen-induced proliferative quiescence in prostate cancer cells: the role of AS3 as its mediator.

Authors:  P Geck; M V Maffini; J Szelei; C Sonnenschein; A M Soto
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

6.  Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region.

Authors:  M Schutte; L T da Costa; S A Hahn; C Moskaluk; A T Hoque; E Rozenblum; C L Weinstein; M Bittner; P S Meltzer; J M Trent
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

7.  Mutation analysis in the BRCA2 gene in primary breast cancers.

Authors:  Y Miki; T Katagiri; F Kasumi; T Yoshimoto; Y Nakamura
Journal:  Nat Genet       Date:  1996-06       Impact factor: 38.330

8.  Low incidence of BRCA2 mutations in breast carcinoma and other cancers.

Authors:  D H Teng; R Bogden; J Mitchell; M Baumgard; R Bell; S Berry; T Davis; P C Ha; R Kehrer; S Jammulapati; Q Chen; K Offit; M H Skolnick; S V Tavtigian; S Jhanwar; B Swedlund; A K Wong; A Kamb
Journal:  Nat Genet       Date:  1996-06       Impact factor: 38.330

9.  Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer.

Authors:  M W Beckmann; F Picard; H X An; C R van Roeyen; S I Dominik; D S Mosny; H G Schnürch; H G Bender; D Niederacher
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

10.  Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13.

Authors:  A M Cleton-Jansen; N Collins; S R Lakhani; J Weissenbach; P Devilee; C J Cornelisse; M R Stratton
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640
View more
  6 in total

1.  APRIN is a unique Pds5 paralog with features of a chromatin regulator in hormonal differentiation.

Authors:  Maricel Maffini; Viktoria Denes; Carlos Sonnenschein; Ana Soto; Peter Geck
Journal:  J Steroid Biochem Mol Biol       Date:  2007-09-12       Impact factor: 4.292

2.  Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions.

Authors:  Brian J Miller; Daolong Wang; Ralf Krahe; Fred A Wright
Journal:  Am J Hum Genet       Date:  2003-09-16       Impact factor: 11.025

3.  Brca2, Pds5 and Wapl differentially control cohesin chromosome association and function.

Authors:  Ziva Misulovin; Michelle Pherson; Maria Gause; Dale Dorsett
Journal:  PLoS Genet       Date:  2018-02-15       Impact factor: 5.917

4.  Downregulation of APRIN expression increases cancer cell proliferation via an interleukin-6/STAT3/cyclin D axis.

Authors:  Min-Shik Sohn; Miae Kang; Seong-Man Kang; Sangwoo Bae
Journal:  Oncol Lett       Date:  2020-11-18       Impact factor: 2.967

5.  APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer.

Authors:  Rachel Brough; Ilirjana Bajrami; Radost Vatcheva; Rachael Natrajan; Jorge S Reis-Filho; Christopher J Lord; Alan Ashworth
Journal:  EMBO J       Date:  2012-01-31       Impact factor: 11.598

Review 6.  PDS5A and PDS5B in Cohesin Function and Human Disease.

Authors:  Nenggang Zhang; Luiza E Coutinho; Debananda Pati
Journal:  Int J Mol Sci       Date:  2021-05-30       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.